The Federal Institute for Drugs and Medical Devices (BfArM) shall, in an appropriate form, give the ethics committee competent under section 33(1) access without undue delay to the sponsor's notification of a substantial modification under Article 75 of Regulation (EU) 2017/745 or Article 71 of Regulation (EU) 2017/746.
Das Bundesinstitut für Arzneimittel und Medizinprodukte ermöglicht der nach § 33 Absatz 1 zuständigen Ethik-Kommission in geeigneter Form den unverzüglichen Zugang zu der Mitteilung des Sponsors über eine wesentliche Änderung nach Artikel 75 der Verordnung (EU) 2017/745 oder Artikel 71 der Verordnung (EU) 2017/746.
Background: Running a clinical trial in Germany · MDR vs IVDR in Germany · EU Authorised Representative and PRRC. We explain what this provision means for your launch, price and timeline — fixed price, in writing.
Unofficial translation for information only. Only the German text is legally binding. German text: consolidated version from gesetze-im-internet.de, retrieved 29 October 2026. Where German statutes use “soll”, “shall” denotes an obligation that admits exceptions in atypical cases. Not legal advice.